The molecular biology of interferon-a from receptor binding to transmembrane signaling

Interferon Therapy of Multiple Sclerosis

Volumn , Issue , 1997, Pages 1-40

  Pfeffer, Lawrence M ^a   Constantinescu, Stefan N ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002792495     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (134)

1. Issacs A, Lindenmann J. Virus interference I: the interferon. Proc Roy Soc Lond 1957; 147:258-267.
2. Nagano Y, Kojima Y. Inhibition de l'infection vaccinate par un facteur liquide dans le tissu infect par le virus homologue. C R Soc Biol 1958; 152: 1627-1629.
3. Aguet M. High affinity binding of 125I-labeled mouse interferon to a specific cell surface receptor. Nature 1980; 284:459-461.
4. Langer J, Pestka S. Interferon receptors. Immunology 1988; 9:875-878.
5. Pfeffer LM. Mechanisms of Interferon Action. Boca Raton, FL: CRC Press, 1987.
6. Rubinstein M, Orchansky P. The interferon receptors. CRC Crit Rev Biochem 1986; 21:249-275.
7. Schindler C, Shuai K, Prezioso VR, Darnell JE. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science 1992; 257:809-813.
8. Fu X-Y. A transcription factor with SH2 and SH3 domains is directly activated by an interferon a-induced cytoplasmic protein tyrosine kinase(s). Cell 1992; 70:323-335.
9. Friedman RL, Stark GR. a-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences. Nature 1985; 314:637-639.
10. Reich NC, Evans B, Levy DE, Fahey D, Knight E, Darnell JE. Interferontranscription of a gene encoding a 15-KD protein depends on an upstream enhancer element. Proc Natl Acad Sci USA 1987; 84:6394-6398.
11. Sadowski HB, Shuai K, Darnell JE Jr, Gilman MZ. A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. Science 1993; 261:1739-1743.
12. Lamer AC, David M, Feldman GM, et al. Tyrosine phosphorylation of DNA binding proteins by multiple cytokines. Science 1993; 261:1730-1736.
13. Muller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK1 complements defects in the interferon-α/β and -y signal transduction. Nature 1993; 366:129-135.
14. Velazquez L, Fellous M, Stark GR, Pelligrini S. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 1992; 70:313-322.
15. Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. TIBS 1994; 19:222-229.
16. Improta T, Schindler C, Horvath CM, Kerr I, Stark GR, Darnell JE. Transcription factor ISGF-3 formation requires phosphorylated Stat91, but Stat113 protein is phosphorylated independently of Stat 91. Proc Natl Acad Sci USA 1994; 91:4776-4780.
17. Pfeffer LM, Eisenkraft BL, Reich NC, et al. Transmembrane signaling by interferon a involves diacylglycerol production and activation of the E isoform of protein kinase C in Daudi cells. Proc Natl Acad Sci USA 1991; 88: 7988-7992
18. Reich NC, Pfeffer LM. Evidence for involvement of protein kinase C in the cellular response to interferon a. Proc Natl Acad Sci USA 1990; 87: 8761-8765.
19. Wang C, Constaninescu SN, MacEwan DJ, et al. Interferona induces protein kinase C-E (PKC-e) gene expression and a 4.7-kb PKC-e—related transcript. Proc Natl Acad Sci USA 1993; 90:6944-6948.
20. Pfeffer LM, Wang C, Fu X-Y, Reich NC, MacEwan DJ, Constantinescu SN. Interferona-induced gene expression and antiviral activity require distinct protein tyrosine kinase- and protein kinase C-dependent pathways. 1996.
21. Constantinescu SN, Croze E, Wang C, et al. The role of the interferon α/β receptor chain 1 in the structure and transmembrane signaling of the interferon alp receptor complex. Proc Natl Acad Sci USA 1994; 91: 9602-9606.
22. Platanias LC, Uddin S, Colamonici OR. Tyrosine phosphorylation of the α and β subunits of the type I interferon receptor: interferon-β selectively induces tyrosine phosphorylation of an a subunit-associated protein. J Biol Chem 1994; 269:17761-17764.
23. Abramovich C, Shulman LM, Ratovitski E, et al. Differential tyrosine phosphorylation in response to interferon-a and interferon-/3 of a surface protein associated with the IFNAR chain of the type-I interferon receptor. EMBO J 1994; 13:5871-5877.
24. Belhumeur P, Lanoix J, Blais Y, Forget D, Steyaert A, Skup D. Action of spontaneously produced beta interferon in differentiation of embryonal carcinoma cells through an autoinduction mechanism. Mol Cell Biol 1993; 13:2846-2857.
25. Garbe C, Krasagakis K. Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 1993; 100:239S-244S.
26. Liberati AM, Schippa M, Portuesi MG, et al. IFN-beta induced biochemical and immunological modifications in hairy leukemia patients. Hematology 1991; 76:375-382.
27. Palmer H, Libby P. Interferon beta. A potential autocrine regulator of human vascular smooth muscle cell growth. Lab Invest 1992; 66:715-721.
28. Vieillard V, Lauret E, Rousseau V, De Maeyer E. Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon beta. Proc Natl Acad Sci USA 1994; 91: 2689-2693.
29. Popik W, Pitha PM. Transcriptional activation of the tat-defective human immunodeficiency type 1 provirus. Virology 1992; 189:435-437.
30. Sica G, Iacopino F, Amadori D, et al. Steroid receptor enhancement by natural interferon-beta in advanced breast cancer. Eur J Cancer 1993; 29: 329-333.
31. Nakajima Y, Konno S, Perruccio L, et al. Effects of IFN beta on growth of human prostatic JCA-1 cells. Biochem Biophys Res Commun 1994; 200: 467-474
32. Asano M, Hayashi M, Yoshida E, Kawade Y, Iwakura Y. Induction of interferon-a by interferon-g, but not of interferon-f3 by interferon-a in the mouse. Virology 1990; 176:30-38.
33. Connelly JF. Interferon beta for multiple sclerosis. Ann Pharm 1994; 28: 610.
34. Clanet M, Blancher A, Calvas P, Rascol O. Interferons and multiple sclerosis. Biomed Pharm 1989; 43:355.
35. Traugott U, Lebon P. Multiple sclerosis: involvement of interferons in lesion pathogenesis. Ann Neurol 1988; 24:243.
36. Panitch HS. Interferons in multiple sclerosis-a review of the evidence. Drugs 1992; 44:946-962.
37. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. Neurology 1993; 43:655-661.
38. Kinnunen E, Timonen T, Pirttila T, et al. Effects of recombinant a-2binterferon therapy in patients with progressive MS. Acta Neurol Scand 1993; 87:457-460.
39. Reis LFL, Ruggner H, Aguet M, Weissman C. The interferon system lacking IRF-1. J Interferon Res 1994; 14:S45.
40. Knop J, Taborski B, De Maeyer-Guignard J. Selective inhibition of the generation of T suppressor cells of contact sensitivity in vitro by interferon. J Immunol 1987; 138:3684-3687.
41. Pelligrini S, John J, Shearer M, Kerr IM, Stark GR. Use of a selectible marker regulated by alpha interferon to obtain mutants in the signaling pathway. Mol Cell Biol 1989; 9:4605-4612.
42. Branca AA, Faltynek CR, D'Alessandro SB, Baglioni C. Interaction of interferon with cellular receptors: internalization and degradation of cellbound interferon. J Biol Chem 1982; 257:13291-13296.
43. Vanden Broecke D, Pfeffer LM. Characterization of interferon-a binding sites on human cell lines. J Interferon Res 1988; 8:803-811.
44. Platanias LC, Pfeffer LM, Cruciani R, Colamonici OR. Characterization of the a subunit of the IFN-α receptor: evidence of N- and O-linked glycosylation and association with other surface proteins. J Immunol 1993; 150: 3382-3388.
45. Constantinescu SN, Blatt LM, Pfeffer LM. The 110-kDa subunit of the interferon-alpha (IFNa) receptor corresponds to an IFNa binding site. 1996.
46. Benoit P, Maguire D, Plavec I, Kocher H, Tovey M, Meyer F. A monoclonal antibody to recombinant IFN-α receptor inhibits the biological activity of several species of human IFN-α, IFN-β, and IFN-w. J Immunol 1993; 150:707-716.
47. Platanias LC, Pfeffer LM, Barton KP, Vardiman JW, Golomb HM, Colamonici OR. Expression of the IFNα receptor in hairy cell leukemia. Br J Hematol 1993; 82:541-546.
48. Wang L, Hertzog PJ, Galanis M, Overall M, Waine GJ, Linnane AW. Structure- function analysis of human IFN-α: mapping of a conformational epitope by homologue scanning. J Immunol 1994; 152:705-715
49. Revel M, Bash D, Ruddle FH. Antibodies to a cell surface component coded by human chromosome 21 inhibit action of interferon. Nature 1976; 260: 139-141.
50. Razziuddin A, Sarkar FH, Dutkowski R, Shulman L, Ruddle FH, Gupta SL. Receptors for human α and β interferon but for for y interferon are specified by human chromosome ;21. Proc Natl Acad Sci USA 1984; 81: 5504-5508. ;
51. Yap WH, Teo TS, McCoy E, Tan YH. Rapid and transient rise in diacylglycerol concentration in Daudi cells exposed to interferon. Proc Natl Acad Sci USA 1986; 83:7765-7769.
52. Tan YH, Schneider EL, Tischfield J, Epstein CJ, Ruddle FH. Human chromosome 21 dosage: effect on the expression of the interferon induced antiviral state. Science 1974; 186:61-63.
53. Colamonici OR, D'Alessandro F, Diaz MO, Gregory SA, Neckers LM, Nordan R. Characterization of three monoclonal antibodies that recognize the interferon α2 receptor. Proc Natl Acad Sci USA 1990; 87:7230-7234.
54. Colamonici OR, Domanski P. Identification of a novel subunit of the type I interferon receptor localized to human chromosome ;21. J Biol Chem 1993; 268:10895-10899.
55. Hertzog PJ, Hwang SY, Holland KA, Tymms MJ, Iannello R, Kola I. A gene on human chromosome 21 located in the region of 21q22.2 to 21q22.3 encodes a factor necessary for signal transduction and antiviral response to type I interferons. J Biol Chem 1994; 269:14088-14093.
56. Soh J, Donnelly RJ, Kotenko S, et al. Identification and sequence of an accessory factor required for activation of the human interferon y receptor. Cell 1994; 76:793-802.
57. Hemmi S, Bohni R, Stark G, Di Marco F, Aguet M. A novel member of the interferon receptor complements functionality of the murine interferon y receptor in human cells. Cell 1994; 76:803-810.
58. Uze G, Lutfalla G, Gresser I. Genetic transfer of a functional human interferon a receptor into mouse cells: cloning and expression of its cDNA. Cell 1990; 60:225-234.
59. Novick D, Cohen B, Rubinstein M. The human interferon a/p receptor: characterization and molecular cloning. Cell 1994; 77:391-400.
60. Faltynek CR, Branca AA, McCandless S, Baglioni C. Characterization of an interferon receptor on human lymphoblastoid cells. Proc Natl Acad Sci USA 1983; 80:3269-3273.
61. Traub A, Feinstein S, Gec M, Lazar A, Mizrahi A. Purification and characterization of the alpha-interferon receptor of human lymphoblastoid (Namalva) cells. J Biol Chem 1984; 259:13872-13877.
62. Zhang ZQ, Fournier A, Tan YH. The isolation of human interferon-beta receptor by wheat germ lectin affinity and immunoabsorbent column chromatographies . J Biol Chem 1986; 261:8017-8021.
63. Joshi AR, Sarkar FH, Gupta SL. Interferon receptors. Crosslinking of human leukocyte interferon alpha-2 to its receptor on human cells. J Biol Chem 1982; 257:13884-13887
64. Thompson MR, Zhang ZQ, Fournier A, Tan YH. Characterization of human beta-interferon-binding sites on human cells. J Biol Chem 1985; 260: 563-567.
65. Eid P, Mogenson K. Detergent extraction of the human interferon-alpha/beta receptor: a soluble form capable of binding interferon. Biochem Biophys Acta 1990; 1034:114-121.
66. Langer J. Radiolabeling of the interferon-a receptor. Biochem Biophys Res Commun 1988; 157:1264-1270.
67. Croze E, Constantinescu SN, Pfeffer LM, et al. Characterization of the type I IFN receptor using monoclonal antibodies. 1996.
68. Pfeffer LM, Basu L, Croze E, Constantinescu SN. The IFNaR1 chain binds human IFNa when expressed in specific cellular contexts. 1996.
69. Colamonici OR, Domanski P, Krolewski JJ, et al. IFNa signalling in cells expressing the variant form of the type I IFN receptor. J Biol Chem 1994; 269:5660-5665.
70. t4k2 tyrosine kinase. Mol Cell Biol 1994; 14:8133-8142.
71. Platanias LC, Sweet ME. Interferon a induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopietic cells. J Biol Chem 1994; 269:3143-3146.
72. Bazan JF. Structure design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA 1990; 87:6934-6938.
73. Bazan JF. Shared architecture of hormone binding domains in type I and II interferon receptors. Cell 1990; 61:753-754.
74. Taga T, Kishimoto T. Cytokine receptors and signal transduction. FASEB J 1992; 6:3387-3396.
75. Stahl N, Yancopoulos GD. The alphas, betas, and kinases of cytokine receptor complexes. Cell 1993; 74:587-590.
76. Colamonici OR, Porterfield B, Domanski P, Constantinescu SN, Pfeffer LM. Complementation of the IFNa response in resistant cells by expression of the cloned subunit of the IFNa receptor: central role of this subunit in IFNa signalling. J Biol Chem 1994; 269:9598-9602.
77. Cleary CM, Donnelly RJ, Soh J, Mariano TM, Pestka S. Knockout and reconstitution of a functional human type I interferon receptor complex. J Biol Chem 1994; 269:18747-18749.
78. Soh J, Mariano TM, Lim J-K, et al. Expression of a functional type I interferon receptor in hamster cells: application of functional yeast artifical chromosome (YAC) screening. J Biol Chem 1994; 269:18102-18110.
79. Mullersman JE, Pfeffer LM. A novel cytoplasmic homology domain in interferon receptors. TIBS 1995; 20:55-56.
80. Wange RL, Malek SN, Desiderio S, Samelson LE. Tandem SH2 domains of ZAP-70 bind to the T cell antigen receptor and CD3e from activated Jurkat T cells. J Biol Chem 1993; 268:19797-19801.
81. Weiss A. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell 1993; 73:209-212
82. Pfeffer LM, Donner DB. The down-regulation of interferona receptors in human lymphoblastoid cells: Relation to cellular responsiveness to the antiproliferative action of a-interferon. Cancer Res 1990; 50:2654-2657.
83. Pfeffer LM, Stebbing N, Donner DB. Cytoskeletal association of human a-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells. Proc Natl Acad Sci USA 1987; 84:3249-3253.
84. Bartsch HH, Pfizenmaier K, Hanusch A, Scheurich P, Ucer U, Nagel GA. Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-a correlates with degree of receptor downregulation. Int J Cancer 1989; 43:235-240.
85. Branca AA, D'Alessandro SB, Baglioni C. Internalization and degradation of human interferon alpha-A bound to bovine MDBK cells: regulation of the decay and resynthesis of receptors. J Interferon Res 1983; 3:465-471.
86. Uzé G, Lutfalla G, Bandu M-T, Proudhon D, Mogensen K. Behavior of a cloned murine α/β receptor expressed in homospecific or heterospecific background. Proc Natl Acad Sci USA 1992; 89:4774-4778.
87. Mouchel-Viehl E, Lutfalla G, Mogensen KE, Uze G. Specific antiviral activities of the human alpha interferons are determined at the level of receptor (IFNAR) structure. FEBS Lett 1992; 313:255-259.
88. Diaz MO, Ziemin S, Le Beau MM, et al. Homozygous deletion of the alpha and betal-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 1988; 85:5259-5263.
89. Donella-Deana A, Marin O, Brunati AM, Cesaro L, Piutti C, Pinna LA. Phosphorylated residues as specificity determinants for an acidophilic protein tyrosine kinase. A study with src and cdc2 derived phosphopeptides. FEBS Lett 1993; 330:141-145.
90. Pearson RB, Kemp BE. Protein kinase phosphorylation site sequences and consensus specificity motifs: tabulations. Methods Enzymol 1991; 200: 62-81.
91. Lim J-K, Xiong J, Carrasco N, Langer JA. Intrinsic ligand binding properties of the human and bovine alpha interferon receptors. FEBS Lett 1994; 350:281-286.
92. Hertzog PJ. 1995: unpublished observations.
93. Muller U, Steinhoff U, Reis LFL, et al. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264:1918-1921.
94. Uze G, Lutfalla G, Mogenson KE. The a/i3 interferons and their receptor and their friends and relatives. J Interferon Res 1995;15:3-26.
95. Colamonici OR, Pfeffer LM, D'Alessandro F, et al. Multichain structure of the IFN-α receptor on hematopoietic cells. J Immunol 1992; 148:2126-2132.
96. Velazquez L, Barbieri G, Mogenson KE, Uze G, Fellous M, Pelligrini S. How does interferon tickle Tyk? J Cell Biochem 1994; S18B:203.
97. Witthuhn BA, Quelle FW, Silvonnoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993; 74:227-236
98. Senda T, Shimazu T, Matsuda S, et al. Three-dimensional crystal structure of recombinant murine interferon-β. EMBO J 1992; 11:3193-3201.
99. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. A Rev Biochem 1987; 56:727-777.
100. Staehlin T, Hobbs DS, Kung H-F, Lai C-Y, Pestka S. Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. J Biol Chem 1981; 256:9750-9754.
101. Ortaldo JR, Mason A, Rehberg E, et al. Effect of recombinant human leukocyte interferons on cytotoxic activity on Natural Killer cells. J Biol Chem 1983; 258:15011-15015.
102. Mitsui Y, Senda T, Shimuza T, Matsuda S, Utsumi J. Structural, functional and evolutionary implications of the three dimensional crystal structure of murine interferon-β. Pharm Ther 1993; 58:93-132.
103. Presnell SR, Cohen FE. Topological distribution of a-helix bundles. Proc Natl Acad Sci USA 1989; 86:6592-6596.
104. Day C, Schwartz B, Li B-L, Pestka S. Engineering disulfide bond greatly increases specific activity of recombinant murine interferon-β. J Interferon Res 1992; 12:139-143.
105. Redlich PN, Hoeprich PD, Colby CB, Grossberg SE. Antibodies that neutralize human β interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. Proc Natl Acad Sci USA 1991; 88: 4040-4044.
106. Arnheiter H, Thomas RM, Leist T, Fountoulakis M, Gutte B. Physiochemical and antigenic properties of synthetic fragments of human leucocyte interferon. Nature 1981; 294:278-280.
107. Ackerman SN, Nedden DZ, Heintzelman M, Hunkapiller M, Zoon K. Biological activity in a fragment of human interferon a. Proc Natl Acad Sci USA 1984; 81:1045-1047.
108. Eichman F, Majarov UA, Kozhlich AT, Noll F, Zav'yalov VP. Biologic activity of synthetic peptides of the sequence of human interferon-alpha. Immunol Lett 1990; 24:233-236.
109. Cheethman BF, McInnes B, Mantamadiotis T, et al. Structure-function studies of human interferon-a enhanced activity on human and murine cells. Antiviral Res 1991; 15:27-40.
110. Streuli M, Hall A, Boll W, Stewart II WE, Nagata S, Weismann C. Target cell specificity of two species of human interferon alpha produced in E. coli and of hybrid molecules derived from them. Proc Natl Acad Sci USA 1981; 78:2848-2852.
111. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor. Crystal structure of the complex. Science 1992; 255:306-311.
112. Meister A, Uze G, Mogenson KE, et al. Biological activities and receptor binding of two human recombinant interferons and their hybrids. J Gen Virol 1986; 67:1633-1643.
113. Stewart AG, Adair JR, Catlin G, et al. Chemical mutagenesis of human; ;interferon-β. Construction, expression in E. coli, and biological activity of sodium bisulfite-induced mutations. DNA 1987; 6:119-128.
114. Ghislan J, Lingwood CA, Fish EN. Evidence for glycosphingolipid modification of the type 1 interferon receptor. J Immunol 1994; 153:3655-3663.
115. Koch CA, Anderson D, Moran MF, Ellis C, Pawson T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 1991; 252:668-674.
116. Pawson T, Schlessinger J. SH2 and SH3 domains. Curr Biol 1993; 3: 434-442.
117. Songyang Z, Shoelson SE, McGlade J, et al. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vay. Mol Cell Biol 1994; 14:2777-2785.
118. Platanias LC, Colamonici OR. Interferon a induces rapid tyrosine phosphorylation of the a subunit of its receptor. J Biol Chem 1992; 267: 24053-24057.
119. Pfeffer LM, Landsberger FR, Tamm I. Beta-interferon-induced time-dependent changes in the plasma membrane lipid bilayer of cultured cells. J Interferon Res 1981; 1:613-620.
120. Pfeffer LM, Kwok BCP, Landsberger FR, Tamm I. Interferon stimulates cholesterol and phosphatidylcholine synthesis but inhibits cholesterol ester synthesis in HeLa-S3 cells. Proc Natl Acad Sci USA 1985; 82:2417-2421.
121. Pfeffer LM, Strulovici B, Saltiel AR. Interferon-a selectively activates the p isoform of protein kinase C through phosphatidylcholine hydrolysis. Proc Natl Acad Sci USA 1990; 87:6537-6541.
122. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258:607-614.
123. Sekiguchi K, Tsukuda M, Ase K, Kikkawa U, Nishizuka Y. Model of activation and kinetic properties of three distinct forms of protein kinase C from rat brain. J Biochem (Tokyo) 1988; 103:759-765.
124. Bacher N, Zisman Y, Berent E, Livneh E. Isolation and characterization of PKC-L, a new member of the protein kinase C-related gene family specifically expressed in lung, skin and heart. Mol Cell Biol 1991; 11:126-133.
125. Osada S, Mizuno K, Saido TC, et al. A phorbol ester receptor/protein kinase, nPKC-eta, a new member of the protein kinase C family predominantly expressed in lung and skin. J Biol Chem 1990; 265:22434-22440.
126. Schaap D, Parker PJ, Bristol A, Kriz R, Knopf J. Unique substrate specificity and regulatory properties of PKC-€: a rationale for diversity. FEBS Lett 1989; 243:351-357.
127. Parker PJ, Kour G, Marais RM, et al. Protein kinase C-a family affair. Mol Cell Endocrinol 1992; 65:1-11.
128. Exton JH. Signalling through phosphatidylcholine breakdown. J Biol Chem 1990; 265:1-4.
129. Schutze S, Potthoff K, Machleidt T, Berkovic D, Weigmann K, Kronke M. TNF activates NF-KB by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992; 71:765-776.
130. Sims SH, Cha Y, Romine MF, Gao P-Q, Gottlieb K, Deisseroth AB. A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter. Mol Cell Biol 1993; 13:690-702.
131. Gutch MJ, Reich NC. Repression of the interferon signal transduction pathway by the adenovirus ElA oncogene. Proc Natl Acad Sci USA 1992; 88: 7914-7918.
132. Kessler DS, Pine R, Pfeffer LM, Levy DE, Darnell JE. Cells resistant to interferon are defective in activation of a promoter-binding factor. EMBO J 1988; 7:3779-3783.
133. Hague SJ, Williams BR. Evidence for two distinct interferon-a-signalling pathways. J Interferon Res 1992; 12:S105.
134. Improta T, Pine R, Pfeffer LM. Interferon-y potentiates the antiviral activity and the expression of interferon-stimulated genes induced by interferon-a in U-937 cells. J Interferon Res 1992; 12:87-94